Long-term clopidogrel therapy improves outcomes after drug-eluting stent placement
This article has no abstract so we have provided the first paragraph of the full text.
Patients who receive coronary stents exhibit reduced rates of thrombosis if they receive antiplatelet therapy with thienopyridines, such as clopidogrel, following implantation. FDA-approved indications currently recommend that patients who undergo percutaneous intervention with drug-eluting stents (DESs) should be treated with clopidogrel for 3–6 months; however, evidence indicates that they might be at risk of late-stent thrombosis after discontinuing the drug. In an observational study, Eisenstein et al. have investigated the association between long-term clopidogrel use, and death and myocardial infarction (MI), after DES or bare metal stent (BMS) placement.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
